Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 17/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | ATR | Q13535 | 1/20 | 0.46 |
| ▸ | F2 | P00734 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6591490 | 0.89 | F10 (0.59) | F10SMN1; SMN2F2 | |
| SCHEMBL6591567 | 0.87 | F10 (0.59) | F10 | |
| SCHEMBL6594066 | 0.85 | ALDH1A1 (0.49) | F10NPC1TSHRRAB9ASMN1; SMN2 | |
| SCHEMBL6593519 | 0.85 | F10 (0.62) | F10TSHRF2 | |
| SCHEMBL7590490 | 0.83 | F10 (0.44) | F10NPC1TSHRRAB9ASMN1; SMN2 | |
| SCHEMBL6594121 | 0.83 | PTPN11 (0.49) | F10TSHRSMN1; SMN2 | |
| SCHEMBL27472592 | 0.82 | F10 (0.61) | F10 | |
| SCHEMBL6590054 | 0.78 | F2 (0.62) | F10F2 | |
| SCHEMBL6261356 | 0.76 | RAB9A (0.64) | F10NPC1TSHRRAB9ASMN1; SMN2 | |
| SCHEMBL6592032 | 0.75 | RAB9A (0.56) | F10NPC1TSHRRAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1040108-B1 | ORTHO-ANTHRANILAMIDE DERIVATIVES AS ANTI-COAGULANTS | SCHERING AG (DE) | 2004-02-25 | — | — | EP | disclosed |
| US-6498185-B1 | ENZYME FACTOR XA INHIBITORS | BERLEX LABORATORIES, INC. | 2002-12-24 | — | — | US | disclosed |
| US-6380221-B1 | FOR THERAPY OF DISEASE-STATES CHARACTERIZED BY THROMBOTIC ACTIVITY | BERLEX LABORATORIES, INC. | 2002-04-30 | — | — | US | disclosed |
| US-6140351-A | FOR TREATING THROMBOSIS | BERLEX LABORATORIES, INC. (US) | 2000-10-31 | — | — | US | disclosed |